GlassScriptPhysician profile
Glenn B Kline
NPI 1689677510
$12,720.51
in general payments reported to CMS, 2019-2025
35 companies · $2,479 in 2025
The $2,479 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $1,510 · 2021: $1,192 · 2022: $1,746 · 2023: $2,271 · 2024: $2,119 · 2025: $2,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,853 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,852.77 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,645.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,455.25 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $2,151.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,543.44 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $541.93 | 2019-2025 | |
| Genentech USA, INC. | $504.18 | 2019-2025 | Xolair |
| Pfizer INC. | $462.51 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $297.47 | 2019-2023 | Airduo Digihaler |
| Takeda Pharmaceuticals U.S.A., INC. | $292.28 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Optinose US, INC. | $232.64 | 2019-2023 | |
| Organon LLC | $220.33 | 2025 | Vtama, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.90 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $141.90 | 2025 | Neffy |
| Amgen INC. | $135.38 | 2022-2024 | Tezspire |
| Kaleo, INC. | $131.78 | 2019-2024 | Auvi-Q |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $101.50 | 2023-2025 | Ryaltris |
| Csl Behring | $101.07 | 2025 | Hizentra |
| Viatris Specialty LLC | $63.09 | 2025 | Yupelri |
| Leo Pharma INC. | $56.91 | 2024-2025 | Adbry, Anzupgo |
| Mylan Specialty L.P. | $52.76 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $48.92 | 2024-2025 | Ebglyss |
| Octapharma USA, INC. | $46.06 | 2020 | |
| Incyte Corporation | $38.42 | 2025 | Opzelura |
| Blueprint Medicines Corporation | $33.79 | 2023 | Ayvakit |
| Greer Laboratories, INC. | $31.70 | 2019 | |
| Abbvie INC. | $26.98 | 2023 | |
| Verona Pharma, INC. | $24.90 | 2025 | Ohtuvayre |
| Pharming Healthcare, INC. | $24.56 | 2025 | Ruconest |
| Aimmune Therapeutics, INC. | $21.24 | 2021 | |
| Hospira, INC. | $21.09 | 2025 | |
| Merck Sharp & Dohme LLC | $20.08 | 2023 | |
| Azurity Pharmaceuticals, INC. | $19.29 | 2025 | Alvesco |
| Grifols USA, LLC | $15.96 | 2019 | |
| Galderma Laboratories, L.P. | $15.95 | 2025 | Nemluvio |
| Alk-Abello, INC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Kline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.